Table a4 Meta-regression for primary and secondary outcomes of mould-active vs fluconazole prophylaxis
Outcome | β | s.e. | P- value |
|---|---|---|---|
Proven or probable IFI | |||
HSCT | −0.07 | 0.35 | 0.831 |
Amphotericin | 0.86 | 0.36 | 0.017 |
Echinocandin | 0.19 | 0.48 | 0.698 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −0.52 | 0.40 | 0.190 |
Blinding | −0.22 | 0.26 | 0.403 |
ITT | −0.24 | 0.25 | 0.350 |
Invasive aspergillosis | |||
HSCT | −0.35 | 0.38 | 0.363 |
Amphotericin | 0.91 | 0.76 | 0.233 |
Echinocandin | −0.90 | 0.91 | 0.326 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −1.12 | 0.64 | 0.080 |
Blinding | −0.10 | 0.36 | 0.780 |
ITT | −0.38 | 0.36 | 0.286 |
Adverse events requiring antifungal treatment discontinuation or modification | |||
HSCT | −0.29 | 0.52 | 0.584 |
Amphotericin | 1.06 | 0.67 | 0.112 |
Echinocandin | −1.09 | 0.68 | 0.112 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −0.83 | 0.48 | 0.086 |
Blinding | −1.12 | 0.30 | 0.0002 |
ITT | −0.13 | 0.59 | 0.833 |
IFI-related mortality | |||
HSCT | −0.10 | 0.48 | 0.831 |
Amphotericin | 0.37 | 0.54 | 0.495 |
Echinocandin | 0.13 | 0.98 | 0.896 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −0.70 | 0.46 | 0.129 |
Blinding | −0.34 | 0.41 | 0.404 |
ITT | −0.42 | 0.39 | 0.282 |
Invasive aspergillosis-related mortality | |||
HSCT | −0.77 | 1.35 | 0.569 |
Amphotericin | 1.17 | 1.40 | 0.403 |
Echinocandin | −1.10 | 1.66 | 0.506 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −0.50 | 0.97 | 0.605 |
Blinding | 0.54 | 1.00 | 0.590 |
ITT | 0.35 | 2.06 | 0.866 |
Overall mortality | |||
HSCT | 0.10 | 0.20 | 0.619 |
Amphotericin | 0.14 | 0.22 | 0.510 |
Echinocandin | −0.16 | 0.30 | 0.591 |
Other azoles | REF | REF | |
Fluconazole ⩾400 mg per day | −0.17 | 0.24 | 0.47 |
Blinding | −0.14 | 0.15 | 0.341 |
ITT | −0.05 | 0.15 | 0.754 |
